NEW YORK (GenomeWeb News) – Investment bank Piper Jaffray has downgraded Illumina to Neutral from Overweight and also has cut its price target on the stock.

Senior Research Analyst William Quirk said in a note published today that the "downgrade reflects concerns over increasingly more challenging 2H13 comps, likely limiting upside in the back half of the year, and with the current valuation."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.